Table 3.

Incidences of HBV reactivation based on HBsAg status and antiviral prophylaxis.

	Total, n	HBV reactivation, n (%)
HBsAg-positive patients	189	14 (7.4)
HBsAg-negative and HBcAb-positive patients	24	2 (8.3)
No antiviral prophylaxis	32	7 (21.9)
Undetectable baseline HBV DNA	25	7 (28)
Detectable baseline HBV DNA	7	0
Antiviral prophylaxis	181	9 (5)
Undetectable baseline HBV DNA	42	5 (11.9)
Detectable baseline HBV DNA	139	4 (2.9)

HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; DNA, deoxyribonucleic acid.